Neural Therapeutics Inc.
NURL
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.80K | 36.50K | 363.90K | 166.20K | 75.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.40K | 40.00K | 367.30K | 174.30K | 83.90K |
| Operating Income | -60.40K | -40.00K | -367.30K | -174.30K | -83.90K |
| Income Before Tax | -288.10K | -46.50K | 125.30K | -690.70K | -81.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -288.10K | -46.50K | 125.30K | -690.70K | -81.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -288.10K | -46.50K | 125.30K | -690.70K | -81.50K |
| EBIT | -60.40K | -40.00K | -367.30K | -174.30K | -83.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 157.40M | 157.40M | 88.90M | 79.28M | 66.53M |
| Average Diluted Shares Outstanding | 157.40M | 157.40M | 88.90M | 79.28M | 66.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |